Tasosartan

Tasosartan
Clinical data
Pregnancy; category	N/A;
ATC code	C09CA05 (WHO) ;
Legal status
Legal status	Withdrawn;
Identifiers
	IUPAC name 2,4-dimethyl-8-{methyl}-5,8-dihydropyridopyrimidin-7(6H)-one;
CAS Number	145733-36-4 ;
PubChem CID	60919;
IUPHAR/BPS	6898;
DrugBank	DB01349 ;
ChemSpider	54890 ;
UNII	48G92V856H;
CompTox Dashboard (EPA)	DTXSID40163148 ;
Chemical and physical data
Formula	C23H21N7O
Molar mass	411.469 g·mol−1
	(what is this?) (verify)

Tasosartan is an angiotensin II receptor antagonist.

It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.^[1]^[2]

References

^ Atkinson AJ, et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 978-0-12-369417-1.
^ Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm. 57 (13): 1231–41. doi:10.1093/ajhp/57.13.1231. PMID 10902066.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Tasosartan
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[1] Atkinson AJ, et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 978-0-12-369417-1.

[2] Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm. 57 (13): 1231–41. doi:10.1093/ajhp/57.13.1231. PMID 10902066.

[1]

[2]

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril Dicarboxylate-containing: Enalapril^# Benazepril Cilazapril Delapril Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+indapamide) Quinapril (+HCT) Ramipril Spirapril Temocapril Trandolapril Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan Eprosartan Fimasartan Irbesartan (+HCT) Losartan (+HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan^§ Telmisartan (+amlodipine, +HCT) Valsartan (+amlodipine, +amlodipine and HCT, +HCT, +nebivolol)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Clinical data

Pregnancy category	N/A
ATC code	C09CA05 (WHO)
Legal status
Legal status	Withdrawn
Identifiers
IUPAC name 2,4-dimethyl-8-{methyl}-5,8-dihydropyridopyrimidin-7(6H)-one
CAS Number	145733-36-4^Y
PubChem CID	60919
IUPHAR/BPS	6898
DrugBank	DB01349^Y
ChemSpider	54890^N
UNII	48G92V856H
CompTox Dashboard (EPA)	DTXSID40163148
Chemical and physical data
Formula	C₂₃H₂₁N₇O
Molar mass	411.469 g·mol⁻¹
^NY (what is this?) (verify)